Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006108 · ClinicalTrials.gov registry record · Phase 1
Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast Cancer
A Phase 1 study, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00006108 is a Phase 1 study that has completed, run by UNC Lineberger Comprehensive Cancer Center.
The verdict
NCT00006108, a Phase 1 study, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining capecitabine, paclitaxel, and trastuzumab in treating patients who have metastatic breast cancer.
Interventions
- DRUG paclitaxel
- DRUG capecitabine
- BIOLOGICAL trastuzumab
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-08 |
| Est. Completion | 2002-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006108
The ClinicalTrials.gov registry entry for NCT00006108 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which paclitaxel is the first listed.
NCT00006108 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006108 about?
NCT00006108 is a clinical study titled "Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining chemothera...
What is the current status of trial NCT00006108?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-08. Estimated completion is 2002-07.
What interventions are being tested in trial NCT00006108?
The interventions under investigation include: paclitaxel (DRUG), capecitabine (DRUG), trastuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00006108?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.